Exclusive special offer and discount title banner vector image

GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET FORECAST 2024-2032

SCOPE OF THE REPORT

Global Antibody Drug Conjugates Contract Manufacturing Market by Phase (Clinical Phase, Commercial Phase) Market by Linker (Cleavable Linkers, Non-cleavable Linkers) Market by Condition (Myeloma, Lymphoma, Breast Cancer, Other Conditions) by Geography

REQUEST CUSTOMIZATION

MARKET OVERVIEW

The global antibody drug conjugates contract manufacturing market was valued at $9952.45 million in 2023 and is expected to reach $31438.09 million by 2032, growing at a CAGR of 12.47% during the forecast period 2024-2032. The base year considered for the study is 2023, and the estimated period is between 2024 and 2032. 

The market study has also analyzed the impact of COVID-19 on the global antibody drug conjugates contract manufacturing market qualitatively as well as quantitatively.

Antibody drug conjugates (ADCs) are compounds created by chemically linking a monoclonal antibody with a drug substance. The monoclonal antibody is designed to target proteins or receptors found on particular cells, such as cancer cells. Once targeted, the linked drug enters these cells and kills them without harming other healthy cells. Pharmaceutical companies rely on third-party specialists, known as contract manufacturing organizations (CMOs), to produce these ADCs. These CMOs possess the expertise, facilities, and equipment needed to manufacture products based on the specifications provided by the contracting company.

Global Antibody Drug Conjugates Contract Manufacturing Market

Read our latest blog on the Antibody Drug Conjugates Contract Manufacturing Market

GROWTH ENABLERS

Key growth enablers of the global antibody drug conjugates contract manufacturing market:

  • Rising demand for targeted therapies
    • Targeted medication usage in cancer treatment is growing, leading to an increased demand for ADC contract manufacturing services. These therapies focus specifically on proteins that regulate cancer cell growth, minimizing harm to healthy tissues.
    • The FDA’s approval of targeted therapies for diverse cancers such as brain, bladder, and gastric cancers underscores the increasing focus on precision medicine. An example of this trend is the recent approval of lifileucel (also known as amtagvi) in February 2024, an innovative cancer treatment using tumor-infiltrating lymphocytes (TILs) to target melanoma, marking the first therapy of its kind for a solid tumor.
    • ADCs represent a promising approach by delivering potent cytotoxic agents directly to cancer cells while minimizing harm to healthy tissues, thus reducing side effects. This has led to ADCs becoming more favored by patients with specific cancers like bladder, ovarian, and breast cancer. As pharmaceutical companies aim to acquire expertise in developing and manufacturing these specialized treatments to address the growing demand for precision cancer therapies, the ADC contract manufacturing market is expanding rapidly. Contract manufacturing organizations play a vital role in meeting this demand by offering specialized expertise and facilities for ADC production.
  • Growing inclination towards contract manufacturing companies as an economical choice
  • Surging global cancer incidence
  • Advancements in drug conjugation technologies

GROWTH RESTRAINTS

Key growth restraining factors of the global antibody drug conjugates contract manufacturing market:

  • High cost of ADC (antibody drug conjugates) development and manufacturing
    • The primary growth restraint in the antibody drug conjugates contract manufacturing market is the high cost linked with ADC development and manufacturing. The intricate nature of ADCs, involving the linking of antibodies to cytotoxic drugs, necessitates complex manufacturing processes and specialized expertise. These processes entail multiple steps, including antibody production, drug synthesis, linker attachment, and purification, all contributing to increased costs.
    • ADC manufacturing requires stringent quality control measures and compliance with regulatory standards, further elevating expenses. Specialized equipment, highly skilled personnel, and state-of-the-art facilities are essential components that significantly contribute to the high costs associated with ADC development and manufacturing.
    • Additionally, the high cost of ADC development and manufacturing may deter smaller pharmaceutical companies or startups from entering the market or pursuing ADC-based therapies. Limited competition may lead to decreased innovation and a slower pace of market growth.
  • Increasing competition from biosimilar ADC (antibody drug conjugates) and generic drugs
  • Stringent regulatory requirements

To Know More About This Report, Request a Free Sample Copy

KEY MARKET TRENDS

Global Antibody Drug Conjugates Contract Manufacturing Market | Top Market Trends

  • The increasing demand for ADCs arises from the urgent need to address the global cancer burden, which represents a significant and escalating public health challenge.
  • As ADCs become more prominent, there is a growing emphasis on ensuring their safety and effectiveness. Contract manufacturing organizations (CMOs) are investing in advanced quality control systems and processes that adhere to international standards. This includes thorough testing at every stage of the manufacturing process to ensure the purity, potency, and stability of ADCs.

MARKET SEGMENTATION

Market Segmentation – Phase, Linker, and Condition –

Market by Phase:

  • Clinical Phase
    • In 2023, the clinical phase segment dominated the phase category. 
    • In the clinical phase, ADC contract manufacturing pharmaceutical companies produce small-scale batches of ADCs for use in clinical trials. These trials aim to evaluate the safety and efficacy of the ADCs in treating specific diseases, often cancer. Further, this phase involves rigorous testing in humans to assess factors such as dosage, administration route, and potential side effects.
    • ADC manufacturers collaborate closely with biopharmaceutical companies developing ADC candidates. This collaboration ensures that the manufacturing processes meet regulatory standards and produce ADCs of consistent quality.
    • CMOs play a crucial role in manufacturing ADCs for clinical trials. This requires expertise in handling complex biological materials and adhering to strict Good Manufacturing Practices (GMP) regulations for clinical research. Completing the clinical phase is a crucial achievement in the development of ADCs, potentially leading to regulatory approval for commercialization.
  • Commercial Phase

Market by Linker:

  • Cleavable Linkers 
  • Non-Cleavable Linkers
    • The non-cleavable linkers segment is predicted to be the fastest-growing linker category over the forecast period. 
    • Non-cleavable linkers in antibody-drug conjugates (ADCs) are chemical structures that attach potent drugs to antibodies, forming robust bonds that endure even within targeted cells. These linkers ensure that the toxic payload remains bound to the antibody post-internalization by the target cell, unlike cleavable linkers that break down under specific conditions. This controlled and steady release amplifies ADC’s effectiveness against cancerous cells.
    • Furthermore, non-cleavable linkers offer simpler design and manufacturing processes, along with greater stability in the bloodstream, potentially reducing the risks of premature payload release. However, their effectiveness depends on the efficiency of antibody degradation within tumor cells, which can be less predictable compared to cleavable linkers. Despite this challenge, advancements in antibody engineering are enhancing the predictability of antibody degradation, making non-cleavable linkers increasingly viable for ADC applications.

Market by Condition:

  • Myeloma 
  • Lymphoma 
  • Breast Cancer 
  • Other Conditions

GEOGRAPHICAL STUDY

Geographical Study based on Four Major Regions:

  • North America: The United States and Canada
    • In North America, numerous eminent pharmaceutical firms and established CMOs like AbbVie, Cambrex Corporation, and Catalent possess extensive experience and expertise in intricate manufacturing processes, including those for ADCs.
    • Additionally, the region boasts a robust supply chain for biopharmaceutical production, modern manufacturing facilities, highly skilled workforces, and government support. These factors further propel the growth of the antibody drug conjugates contract manufacturing industry in North America.
    • Regulatory bodies in North America, such as the Food and Drug Administration (FDA), have established specific guidelines for ADC development and approval, providing a comparatively predictable course to market entry.
  • Europe: The United Kingdom, Germany, France, Italy, Spain, Switzerland, Nordic Countries, and Rest of Europe 
  • Asia-Pacific: China, Japan, India, South Korea, Thailand, Australia & New Zealand, and Rest of Asia-Pacific
  • Rest of World: Latin America, the Middle East & Africa

MAJOR PLAYERS

Major players in the global antibody drug conjugates contract manufacturing market:

  • Sterling Pharma Solutions
  • Recipharm AB
  • Lonza Group
  • WuXi Biologics 
  • Merck KGaA
  • AbbVie Inc (AbbVie Contract Manufacturing)

Key strategies adopted by some of these companies:

  • Lonza acquired Synaffix BV (Synaffix), a Dutch biotech firm specializing in commercializing its clinical-stage technology platform for developing ADCs, in June 2023.
  • WuXi Biologics announced the launch of WuXiaADCC PLUSTM, a novel platform designed for the development and manufacture of afucosylated antibodies, in January 2024. These antibodies can significantly enhance the antibody-dependent cell-mediated cytotoxicity (ADCC) effects, which is a crucial aspect of targeted antibody-based immunotherapy. Derived from the WuXi Biologics WuXiaTM cell line, the WuXiaADCC PLUSTM platform is expected to meet the growing global demand for afucosylated antibody production.

REPORT SYNOPSIS

REPORT SCOPEDETAILS
Market Forecast Years2024-2032
Base Year2023
Market Historical Years2018-2022
Forecast Units

Revenue ($ Million)

Segments AnalyzedPhase, Linker, and Condition
Geographies AnalyzedNorth America, Europe, Asia-Pacific, and Rest of World
Companies AnalyzedSterling Pharma Solutions, Recipharm AB, Lonza Group, Piramal Pharma Solutions, AbbVie Inc (AbbVie Contract Manufacturing), Merck KGaA, Catalent Inc, Sartorius AG, WuXi Biologics, Samsung Biologics Co Ltd, Cambrex Corporation, Cerbios-Pharma SA
TABLE OF CONTENTS
  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. METHODOLOGY
    3. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. MARKET OVERVIEW
    3. SCOPE OF STUDY
    4. CRISIS SCENARIO ANALYSIS
    5. MAJOR MARKET FINDINGS
      1. INCREASING COLLABORATION BETWEEN KEY CONTRACT MANUFACTURERS (CMOS)
      2. CHALLENGES IN NAVIGATING COMPLEX REGULATORY REQUIREMENTS
  3. MARKET DYNAMICS
    1. KEY DRIVERS
      1. RISING DEMAND FOR TARGETED THERAPIES
      2. GROWING INCLINATION TOWARDS CONTRACT MANUFACTURING COMPANIES AS AN ECONOMICAL CHOICE
      3. SURGING GLOBAL CANCER INCIDENCE
      4. ADVANCEMENTS IN DRUG CONJUGATION TECHNOLOGIES
    2. KEY RESTRAINTS
      1. HIGH COST OF ADC (ANTIBODY DRUG CONJUGATES) DEVELOPMENT AND MANUFACTURING
      2. INCREASING COMPETITION FROM BIOSIMILAR ADC (ANTIBODY DRUG CONJUGATES) AND GENERIC DRUGS
      3. STRINGENT REGULATORY REQUIREMENTS
  4. KEY ANALYTICS
    1. KEY MARKET TRENDS
      1. RISING DEMAND FOR ADCS
      2. GROWING FOCUS ON ADC QUALITY AND REGULATORY COMPLIANCE
    2. PORTER’S FIVE FORCES ANALYSIS
      1. BUYERS POWER
      2. SUPPLIERS POWER
      3. SUBSTITUTION
      4. NEW ENTRANTS
      5. INDUSTRY RIVALRY
    3. GROWTH PROSPECT MAPPING
      1. GROWTH PROSPECT MAPPING FOR NORTH AMERICA
      2. GROWTH PROSPECT MAPPING FOR EUROPE
      3. GROWTH PROSPECT MAPPING FOR ASIA-PACIFIC
      4. GROWTH PROSPECT MAPPING FOR REST OF WORLD
    4. MARKET MATURITY ANALYSIS
    5. MARKET CONCENTRATION ANALYSIS
    6. KEY BUYING CRITERIA
      1. EXPERTISE AND EXPERIENCE
      2. MANUFACTURING CAPACITY
      3. REGULATORY COMPLIANCE
      4. QUALITY CONTROL
      5. COST
    7. REGULATORY FRAMEWORK
  5. MARKET BY PHASE
    1. CLINICAL PHASE
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    2. COMMERCIAL PHASE
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
  6. MARKET BY LINKER
    1. CLEAVABLE LINKERS
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    2. NON-CLEAVABLE LINKERS
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
  7. MARKET BY CONDITION
    1. MYELOMA
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    2. LYMPHOMA
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    3. BREAST CANCER
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    4. OTHER CONDITIONS
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
  8. GEOGRAPHICAL ANALYSIS
    1. NORTH AMERICA
      1. MARKET SIZE & ESTIMATES
      2. NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET DRIVERS
      3. NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET CHALLENGES
      4. KEY PLAYERS IN NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET
      5. COUNTRY ANALYSIS
        1. UNITED STATES
          1. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
        2. CANADA
          1. CANADA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
    2. EUROPE
      1. MARKET SIZE & ESTIMATES
      2. EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET DRIVERS
      3. EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET CHALLENGES
      4. KEY PLAYERS IN EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET
      5. COUNTRY ANALYSIS
        1. UNITED KINGDOM
          1. UNITED KINGDOM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
        2. GERMANY
          1. GERMANY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
        3. FRANCE
          1. FRANCE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
        4. ITALY
          1. ITALY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
        5. SPAIN
          1. SPAIN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
        6. SWITZERLAND
          1. SWITZERLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
        7. NORDIC COUNTRIES
          1. NORDIC COUNTRIES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
        8. REST OF EUROPE
          1. REST OF EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
    3. ASIA-PACIFIC
      1. MARKET SIZE & ESTIMATES
      2. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET DRIVERS
      3. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET CHALLENGES
      4. KEY PLAYERS IN ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET
      5. COUNTRY ANALYSIS
        1. CHINA
          1. CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
        2. JAPAN
          1. JAPAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
        3. INDIA
          1. INDIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
        4. SOUTH KOREA
          1. SOUTH KOREA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
        5. THAILAND
          1. THAILAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
        6. AUSTRALIA & NEW ZEALAND
          1. AUSTRALIA & NEW ZEALAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
        7. REST OF ASIA-PACIFIC
          1. REST OF ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
    4. REST OF WORLD
      1. MARKET SIZE & ESTIMATES
      2. REST OF WORLD ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET DRIVERS
      3. REST OF WORLD ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET CHALLENGES
      4. KEY PLAYERS IN REST OF WORLD ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET
      5. REGIONAL ANALYSIS
        1. LATIN AMERICA
          1. LATIN AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
        2. MIDDLE EAST & AFRICA
          1. MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE & OPPORTUNITIES
  9. COMPETITIVE LANDSCAPE
    1. KEY STRATEGIC DEVELOPMENTS
      1. MERGERS & ACQUISITIONS
      2. PRODUCT LAUNCHES & DEVELOPMENTS
      3. PARTNERSHIPS & AGREEMENTS
    2. COMPANY PROFILES
      1. ABBVIE INC (ABBVIE CONTRACT MANUFACTURING)
        1. COMPANY OVERVIEW
        2. SERVICES LIST
        3. STRENGTHS & CHALLENGES
      2. CAMBREX CORPORATION
        1. COMPANY OVERVIEW
        2. SERVICES LIST
      3. CATALENT INC
        1. COMPANY OVERVIEW
        2. SERVICES LIST
        3. STRENGTHS & CHALLENGES
      4. CERBIOS-PHARMA SA
        1. COMPANY OVERVIEW
        2. SERVICES LIST
      5. LONZA GROUP
        1. COMPANY OVERVIEW
        2. SERVICES LIST
        3. STRENGTHS & CHALLENGES
      6. MERCK KGAA
        1. COMPANY OVERVIEW
        2. SERVICES LIST
        3. STRENGTHS & CHALLENGES
      7. PIRAMAL PHARMA SOLUTIONS
        1. COMPANY OVERVIEW
        2. SERVICES LIST
        3. STRENGTHS & CHALLENGES
      8. RECIPHARM AB
        1. COMPANY OVERVIEW
        2. SERVICES LIST
        3. STRENGTHS & CHALLENGES
      9. SARTORIUS AG
        1. COMPANY OVERVIEW
        2. SERVICES LIST
        3. STRENGTHS & CHALLENGES
      10. SAMSUNG BIOLOGICS CO LTD
        1. COMPANY OVERVIEW
        2. SERVICES LIST
        3. STRENGTHS & CHALLENGES
      11. STERLING PHARMA SOLUTIONS
        1. COMPANY OVERVIEW
        2. SERVICES LIST
        3. STRENGTHS & CHALLENGES
      12. WUXI BIOLOGICS
        1. COMPANY OVERVIEW
        2. SERVICES LIST
        3. STRENGTHS & CHALLENGES

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING

TABLE 2: REGULATORY FRAMEWORK

TABLE 3: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY PHASE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 4: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY PHASE, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 5: GLOBAL CLINICAL PHASE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 6: GLOBAL CLINICAL PHASE MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 7: GLOBAL COMMERCIAL PHASE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 8: GLOBAL COMMERCIAL PHASE MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 9: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY LINKER, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 10: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY LINKER, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 11: GLOBAL CLEAVABLE LINKERS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 12: GLOBAL CLEAVABLE LINKERS MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 13: GLOBAL NON-CLEAVABLE LINKERS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 14: GLOBAL NON-CLEAVABLE LINKERS MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 15: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY CONDITION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 16: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY CONDITION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 17: GLOBAL MYELOMA MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 18: GLOBAL MYELOMA MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 19: GLOBAL LYMPHOMA MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 20: GLOBAL LYMPHOMA MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 21: GLOBAL BREAST CANCER MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 22: GLOBAL BREAST CANCER MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 23: GLOBAL OTHER CONDITIONS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 24: GLOBAL OTHER CONDITIONS MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 25: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 26: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY GEOGRAPHY, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 27: NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 28: NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 29: KEY PLAYERS OPERATING IN NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET

TABLE 30: EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 31: EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 32: KEY PLAYERS OPERATING IN EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET

TABLE 33: ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 34: ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 35: KEY PLAYERS OPERATING IN ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET

TABLE 36: REST OF WORLD ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 37: REST OF WORLD ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY REGION, FORECAST YEARS, 2024-2032 (IN $ MILLION)

TABLE 38: KEY PLAYERS OPERATING IN REST OF WORLD ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET

TABLE 39: LIST OF MERGERS & ACQUISITIONS

TABLE 40: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 41: LIST OF PARTNERSHIPS & AGREEMENTS

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: GROWTH PROSPECT MAPPING FOR NORTH AMERICA

FIGURE 4: GROWTH PROSPECT MAPPING FOR EUROPE

FIGURE 5: GROWTH PROSPECT MAPPING FOR ASIA-PACIFIC

FIGURE 6: GROWTH PROSPECT MAPPING FOR REST OF WORLD

FIGURE 7: MARKET MATURITY ANALYSIS

FIGURE 8: MARKET CONCENTRATION ANALYSIS

FIGURE 9: KEY BUYING CRITERIA

FIGURE 10: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, GROWTH POTENTIAL, BY PHASE, IN 2023

FIGURE 11: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY CLINICAL PHASE, 2024-2032 (IN $ MILLION)

FIGURE 12: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY COMMERCIAL PHASE, 2024-2032 (IN $ MILLION)

FIGURE 13: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, GROWTH POTENTIAL, BY LINKER, IN 2023

FIGURE 14: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY CLEAVABLE LINKERS, 2024-2032 (IN $ MILLION)

FIGURE 15: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY NON-CLEAVABLE LINKERS, 2024-2032 (IN $ MILLION)

FIGURE 16: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, GROWTH POTENTIAL, BY CONDITION, IN 2023

FIGURE 17: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY MYELOMA, 2024-2032 (IN $ MILLION)

FIGURE 18: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY LYMPHOMA, 2024-2032 (IN $ MILLION)

FIGURE 19: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY BREAST CANCER, 2024-2032 (IN $ MILLION)

FIGURE 20: GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, BY OTHER CONDITIONS, 2024-2032 (IN $ MILLION)

FIGURE 21: NORTH AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)

FIGURE 22: UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 23: CANADA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 24: EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)

FIGURE 25: UNITED KINGDOM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 26: GERMANY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 27: FRANCE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 28: ITALY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 29: SPAIN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 30: SWITZERLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 31: NORDIC COUNTRIES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 32: REST OF EUROPE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 33: ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)

FIGURE 34: CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 35: JAPAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 36: INDIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 37: SOUTH KOREA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 38: THAILAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 39: AUSTRALIA & NEW ZEALAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 40: REST OF ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 41: REST OF WORLD ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, REGIONAL OUTLOOK, 2023 & 2032 (IN %)

FIGURE 42: LATIN AMERICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)

FIGURE 43: MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, 2024-2032 (IN $ MILLION)

FAQ’s

FAQs

The Asia-Pacific is anticipated to be the fastest-growing region in the global antibody drug conjugates contract manufacturing market over the forecasted period.

The global ADC contract manufacturing market is estimated to grow at a CAGR of 12.47% during the forecast period.

The antibody-drug conjugate manufacturing process involves several steps, including cell line development, process optimization, scaled-up production, conjugation chemistry, and analytical testing. Contract manufacturing pharmaceutical companies specializing in ADCs offer these services to pharmaceutical companies developing ADC-based therapies.

Request Customization
Request Customization
Request Customization